BioWorld: The Daily Biopharmaceutical and Medical Technology …
Ring Therapeutics Inc. has joined forces with Singapore’s Agency for Science, Technology, and Research and with the Singapore Eye Research Institute to advance the first... In the newest BioWorld Insider podcast, Victoria Lipinska, the America's lead for Quantum Innovation Centers at IBM Quantum, talks about the future of drug development ...
US FDA clears Cobenfy, first new schizophrenia drug in decades
Sep 27, 2024 · The FDA has approved Cobenfy, a dual M1/M4 muscarinic agonist that offers a fundamentally different approach to treating schizophrenia. The fixed dose combination of xanomeline-trospium is the first to act via a novel mechanism for the serious psychiatric disorder in over 50 years, finally expanding the treatment options beyond dopamine-targeted therapies.
BioWorld MedTech: The Daily Medical Technology News Source
Med-tech funding rises, driven by private investments and follow-ons. Med-tech firms raised $22.71 billion in financings through October, an increase of 46% over the $15.59 billion raised during the same period in 2023. October’s value totaled $1.43 billion, up from $1.02 billion in September, but down from August's $3.67 billion.
Coronavirus - Articles - BioWorld
Nov. 5, 2024. No Comments. The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus pandemic. They are available for free with registration. Note that we have added three critical tables, which are continuously updated: Vaccines and therapeutics in …
China - Articles - BioWorld
Oct. 21, 2024. By Tamra Sami. No Comments. After raising $42 million in a series C1 round, Lanova Medicines Ltd. is advancing its lead phase III antibody-drug conjugate LM-302 that targets Claudin 18.2, as well as LM-299, an anti-PD-1/VEGF bispecific antibody, and LM-108, an anti-CCR8 monoclonal antibody. “Proceeds from this financing will ...
Patents - Articles - Page 6 | BioWorld
Oct 18, 2024 · Chengdu Zeling Biomedical Technology patents new NLRP3 inflammasome inhibitors. Chengdu Zeling Biomedical Technology Co. Ltd. has disclosed NLRP3 inflammasome inhibitors reported to be useful for the treatment of cancer, inflammatory, autoimmune, cardiovascular, renal, gastrointestinal, respiratory and neurological disorders.
BBO-8520, a novel KRAS G12C GTP/GDP dual inhibitor - BioWorld
BBO-8520, a novel KRAS G12C GTP/GDP dual inhibitor. Oct. 31, 2022. Researchers from Bridgebio Pharma Inc. presented preclinical characterization of the novel next-generation KRAS G12C GTP/GDP dual inhibitor candidate, BBO-8520, being developed for the treatment of cancer. BioWorld Science Conferences Cancer.
Cancer - Articles - BioWorld
Oct 31, 2024 · By Marian (YoonJee) Chu. No Comments. Backed by AI technology, Aigen Sciences Inc. raised ₩12 billion (US$8.8 million) in a series A financing round to further advance its cancer and rare disease drug pipelines. Aigen said Oct. 16 that the series A round was joined by existing investors Partners Investment, Quad Investment Management and ...
Neko Health secures $65M for AI-driven full body scan technology
Jul 20, 2023 · Neko Health AB reported it has secured $67 million in investment capital to develop its artificial intelligence (AI)-driven full body scanner beyond its home country, Sweden. This series A round was led by Berlin-based Lakestar Advisors GmbH, with participation from Atomico (UK) Partners LLP from London and General Catalyst Group Management LLC …
| BioWorld
Aug. 11, 2022. Aro Biotherapeutics announced that the FDA has granted orphan drug designation for ABX-1100, its investigational Centyrin-siRNA conjugate, for the treatment of Pompe disease. BioWorld Science Endocrine/metabolic. After missing out on the glucagon-like peptide 1 obesity market, Sanofi SA is prospecting for next-generation drugs ...